Sugi Predict

Sugi Predict / Compounds / SCHEMBL566097

SCHEMBL566097

SCHEMBL566097

C#CCNc1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.53
▸ CA12 O43570 2/20 0.53
▸ CA9 Q16790 2/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ MAOA P21397 3/20 0.42
▸ MAOB P27338 3/20 0.42
▸ PYCR1 P32322 2/20 0.41
▸ MMP9 P14780 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ ADAM17 P78536 1/20 0.40
▸ CA4 P22748 1/20 0.39
▸ GAA P10253 3/20 0.38
▸ KCNH3 Q9ULD8 1/20 0.38
▸ RPS6KA2 Q15349 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11741377 0.79 MAPT (0.58) MAPTCA12CA9CA1CA2
SCHEMBL30726070 0.78 PYCR1 (0.39) MAPTCA12CA9CA1CA2
SCHEMBL28186756 0.77 PYCR1 (0.53) MAPTCA12CA9CA1CA2
SCHEMBL11078522 0.77 MAPT (0.53) MAPTCA12CA9CA1CA2
SCHEMBL17076659 0.77 CA12 (0.58) MAPTCA12CA9CA1CA2
SCHEMBL31592520 0.77 CA12 (0.53) MAPTCA12CA9CA1CA2
SCHEMBL196987 0.77 CA2 (0.46) MAPTCA9CA2GAARPS6KA2
SCHEMBL4225554 0.77 CA12 (0.53) MAPTCA12CA9CA1CA2
SCHEMBL29415181 0.77 MAPT (0.44) MAPTCA12CA9CA1CA2
SCHEMBL28186751 0.77 MAPT (0.44) MAPTCA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 — — US disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
CN-119161324-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2024-12-20 — — CN disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
EP-3911645-B1 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE UNIV LILLE (FR) 2022-12-07 — — EP disclosed
WO-2022247676-A1 COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 南京康屹生物医药中心(有限合伙) 2022-12-01 — — WO disclosed
WO-2022247676-A1 COMPOUND WITH DIPYRROLOPYRIDINE STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 南京康屹生物医药中心(有限合伙) 2022-12-01 — — WO disclosed
CN-115385911-A Compound with dipyrrolopyridine structure, preparation method and medical application 南京康屹生物医药中心(有限合伙) 2022-11-25 — — CN disclosed
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-10-06 — — US disclosed
US-8592399-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2013-11-26 — — US disclosed
US-8383657-B2 Thiazolylidine urea and amide derivatives and methods of use thereof ABBOTT LABORATORIES (US) 2013-02-26 — — US disclosed
US-20120034270-A1 S1P Receptors Modulators AKAAL PHARMA PTY LTD (AU) 2012-02-09 — — US disclosed
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD (AU) 2011-12-29 — — US disclosed
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-06-25 — — US disclosed
CN-1361772-A Substituted heteroaryloxyacetanilides and their use as herbicides BAYER AG (DE) 2002-07-31 — — CN disclosed
EP-0426666-A1 SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS WARNER-LAMBERT COMPANY (US) 1991-05-15 — — EP disclosed
US-4857530-A THYMIDYLATE SYNTHASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1989-08-15 — — US disclosed
EP-0316657-A1 Substituted quinazolinones as anticancer agents WARNER-LAMBERT COMPANY (US) 1989-05-24 — — EP disclosed
WO-1989004307-A1 SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS WARNER-LAMBERT COMPANY (US) 1989-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF NMUR1, NMUR2, PAM MAPT 465/4885CA12 2742/4885CA9 1201/4885
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS MAPT 4269/4885CA12 3754/4885CA9 3772/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS MAPT 4269/4885CA12 3754/4885CA9 3772/4885
US-20120034270-A1 S1P Receptors Modulators S1PR1, S1PR5, S1PR3 MAPT 4146/4885CA12 4777/4885CA9 4761/4885
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS MAPT 4269/4885CA12 3754/4885CA9 3772/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS MAPT 4269/4885CA12 3754/4885CA9 3772/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 MAPT 2371/4885CA12 3515/4885CA9 2810/4885
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof S1PR1, S1PR5, S1PR2 MAPT 4096/4885CA12 4613/4885CA9 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.